Predrag Sikiric, M.D., Ph.D.
University of Zagreb
BPC-157 cytoprotection and VEGF upregulation research.
KLOW is a compounded quad-peptide repair stack formulated in an 80 mg vial containing BPC-157 (15 mg), TB-500 (15 mg), GHK-Cu (50 mg), and KPV (15 mg). Each peptide targets a distinct, non-overlapping healing pathway: VEGF-driven collagen remodeling (BPC-157), actin-regulated cell migration (TB-500), gene-modulated extracellular matrix stabilization (GHK-Cu), and NF-κB pathway inhibition for immune control (KPV).
Mechanism of action
- BPC-157: VEGF-driven angiogenesis and collagen remodeling.
- TB-500: actin-regulated cell migration and angiogenic support.
- GHK-Cu: gene-modulated extracellular matrix stabilization.
- KPV: NF-κB pathway inhibition supporting immune-control models.
Research highlights
- No published clinical trial evaluates this exact four-peptide stack.
- Each individual component has independent peer-reviewed preclinical literature.
Regulatory note: The exact KLOW formulation has not been evaluated in published randomized controlled trials.